Do adrenergic alpha‐antagonists increase the risk of poor cardiovascular outcomes? A systematic review and meta‐analysis

Due to concerns regarding neurohormonal activation and fluid retention, adrenergic alpha‐1 receptor antagonists (A1Bs) are generally avoided in the setting of heart disease, namely, symptomatic heart failure (HF) with reduced ejection fraction (HFrEF). However, this contraindication is mainly suppor...

Descripción completa

Detalles Bibliográficos
Autores principales: Sousa, José Pedro, Mendonça, Diogo, Teixeira, Rogério, Gonçalves, Lino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715777/
https://www.ncbi.nlm.nih.gov/pubmed/35894772
http://dx.doi.org/10.1002/ehf2.14012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715777/
https://www.ncbi.nlm.nih.gov/pubmed/35894772
http://dx.doi.org/10.1002/ehf2.14012

Ejemplares similares